Michel, Maurice
Wahl, Alisha
Anders, Malena
Alqahtani, Saleh A.
Kremer, Wolfgang M.
Galle, Peter R.
Labenz, Christian
Grimm, Daniel
Sprinzl, Martin
Schattenberg, Jörn M. http://orcid.org/0000-0002-4224-4703
Funding for this research was provided by:
Gilead Sciences
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Article History
Accepted: 5 August 2022
First Online: 22 August 2022
Declarations
:
: JMS has acted as a consultant to Boehringer Ingelheim, BMS, Genfit, Gilead Sciences, Intercept Pharmaceuticals, Madrigal, Novartis, Novo Nordisk, Nordic Bioscience, Pfizer, Roche, Sanofi, Siemens Healthcare GmbH. Research Funding: Gilead Sciences, Boehringer Ingelheim. Speakers Bureau: Falk Foundation MSD Sharp & Dohme GmbH. The other authors declare that they have no competing interests.
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Landesärztekammer Rhineland-Palatine Nr. 873.199.10 (7208).”
: Informed consent was obtained from all patients involved in the study.